LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akciju saraksts・Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

16.65 2.59

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.14

Max

16.88

Galvenie mērījumi
By Trading Economics
Ienākumi	614M 331M
Pārdošana	288M 731M
P/E Sektora vidējais	48.586 49.888
EPS	3.16
Peļņas marža	45.287
Darbinieki	835
EBITDA	628M 375M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+36.45% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-531M 1.8B
Iepriekšējā atvēršanas cena	14.06
Iepriekšējā slēgšanas cena	16.65

Ziņu noskaņojums

By Acuity

50%

155 / 344 Rangs Healthcare

Sarepta Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 29. jūl. 15:04 UTC

Galvenie tirgus virzītāji

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

2025. g. 21. jūl. 11:31 UTC

Galvenie tirgus virzītāji

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

2026. g. 6. maijs 22:50 UTC

Peļņas

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

2026. g. 26. janv. 09:55 UTC

Karstas akcijas

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

2025. g. 4. nov. 14:39 UTC

Peļņas

Karstas akcijas

Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ

2025. g. 4. nov. 12:45 UTC

Peļņas

These Stocks Are Moving the Most Today: Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More -- Barrons.com

2025. g. 11. aug. 11:48 UTC

Peļņas

These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

2025. g. 11. aug. 11:11 UTC

Peļņas

These Stocks Are Moving the Most Today: C3.ai, Coinbase, MicroStrategy, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

2025. g. 29. jūl. 21:11 UTC

Peļņas

These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More -- Barrons.com

2025. g. 29. jūl. 12:14 UTC

Peļņas

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More -- Barrons.com

2025. g. 29. jūl. 11:46 UTC

Peļņas

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, UPS, Boeing, PayPal, Sarepta, Whirlpool, and More -- Barrons.com

2025. g. 21. jūl. 12:53 UTC

Peļņas

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

2025. g. 21. jūl. 11:17 UTC

Peļņas

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

2025. g. 21. jūl. 10:25 UTC

Peļņas

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

2025. g. 21. jūl. 09:50 UTC

Peļņas

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

2025. g. 21. jūl. 09:12 UTC

Peļņas

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

2025. g. 17. jūl. 16:44 UTC

Peļņas

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

2025. g. 17. jūl. 13:48 UTC

Peļņas

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

2025. g. 17. jūl. 10:57 UTC

Peļņas

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

2025. g. 17. jūl. 09:08 UTC

Karstas akcijas

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

2025. g. 17. jūn. 09:10 UTC

Karstas akcijas

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

2025. g. 17. jūn. 08:59 UTC

Karstas akcijas

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

2025. g. 16. jūn. 08:55 UTC

Karstas akcijas

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Salīdzinājums

Cenas izmaiņa

Sarepta Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

36.45% augšup

Prognoze 12 mēnešiem

Vidējais 22.16 USD 36.45%

Augstākais 38 USD

Zemākais 5 USD

Pamatojoties uz 20 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sarepta Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

20 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 20 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Sarepta Therapeutics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

155 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.